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Abstract
OBJECTIVE: To explore the mechanism of action of
Xixin decoction (XXD) for the prevention and treat-
ment of sporadic Alzheimer disease (SAD) by inves-
tigating the effects of XXD on the phosphorylation
of Thr231 and Ser422 sites of tau protein.
METHODS: Specific pathogen-free (SPF) male
Sprague-Dawley (SD) rats with SAD were randomly
divided into six groups: sham-operated, model (in-
tracerebroventricular injection of Streptozotocin,
ICV-STZ), donepezil (0.92 mg/kg), XXD low-dose
(7.61 g/kg-1·d-1), moderate-dose (15.21 g/kg-1·d-1),
and high-dose (30.42 g/kg-1·d-1). Immunohisto-
chemistry and western immunoblotting were used
to detect the phosphorylation at Thr231 and
Ser422 sites of tau protein.
RESULTS: XXD different dose groups decreased to
varying degrees the expression of phosphorylated
tau at P-Thr231 and P-Ser422 sites in the hippocam-
pus of SAD rats. No significant difference was found
between the donepezil and model group.
CONCLUSION: XXD may prevent SAD pathological
progress by inhibiting hyperphosphorylation at the
key sites of tau proteins.
© 2013 JTCM. All rights reserved.
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INTRODUCTION
With the accelerated process of population aging, Al-
zheimer disease (AD) has become a common disease
threatening people's health and their quality of life.
However, the mechanisms underlying this disease re-
main unclear. Consequently, no effective treatment ex-
ists for AD. Extracellular senile plaque (SP) deposition
and intracellular neurofibrillary tangles (NFT) are typi-
cal characteristic hallmark pathologies of AD.1 Abnor-
mal hyperphosphorylation of neural tubulin tau causes
their aggregation and thus forms NFTs in AD pa-
tients.2 Recently, abnormal hyperphosphorylation of
neural tubulin tau has been shown to induce neurode-
generation via cellular toxicity rather than loss of bio-
logical activity to these cells.3 Phosphorylation of tau
proteins on many sites is toxic to neurons and inhibits
normal related tubulin.4
Xixin decoction (XXD), a well-known formula pre-
scribed by Shiduo Chen (a renowned physician in the
Qing Dynasty), has been used for the treatment of AD
in China.5 This formula increases Qi and Yang, re-
moves Yin pathogenic factors, relieves stagnation, re-
solves phlegm, and balances Yin and Yang.6 According
to modern pharmacological research, major ingredients
in this formula, such as ginseng and acorus gramineus,
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exert prominent nootropic and anti-aging effects. This
study was to investigate the effects of XXD on tau
phosphorylation, by evaluating phosphorylated
(P)-Thr231 and P-Ser422 which are important pro-
moters of tau toxicity, and explore its possible mecha-
nism on improving learning and memory ability of spo-
radic Alzheimer disease (SAD),7 and prohibition of ab-
normal hyperphosphorylation of neural tubulin tau in
SAD brain and prevention of SAD progression.
METHODS
Animals
Eighty-four specific pathogen-free male Sprague-Daw-
ley rats (270±20) g were purchased from the Experi-
mental Animal Center of The Fourth Military Medical
University (Certificate No. 0034642), and were ran-
domly divided into six groups by random number
method (14 rats per group): (a) sham-operated, (b)
model (intracerebroventricular injection of Streptozoto-
cin, ICV-STZ), (c) donepezil, (d) XXD low-dose(YL),
(e) XXD moderate-dose(YM), and (f ) XXD high-dose
(YH). The animals were kept in a barrier system (Ap-
proval No. SYXK2007-2010) with ad libitum access to
water and food. The temperature was kept at
22℃-26℃ and humidity at 30%-40%. The experimen-
tal procedures, and animal use and care protocols, were
approved by the Committee on Ethical Use of Animals
of Shaanxi University of Chinese Medicine.
Medicines and reagents
The ingredients of XXD included: Renshen (Radix
Ginseng), Banxia (Rhizoma Pinelliae), Fushen (Poria
Cum Radix Pini), Fuzi (Radix Aconiti Lateralis Prepara-
ta), Shichangpu (Rhizoma Acori Tatarinowii) and some
other Chinese herbs. XXD was provided in the form of
granules by Sanjiu Medical and Pharmaceutical Co.,
Ltd. (Shenzhen, China) (Approval No. 0908032).
Streptozotocin was obtained from by Merck & Co.,
Inc (Whitehouse Station, NJ, USA) (Approval No.
K0050). Donepezil was purchased from Xi'an Haixin
Pharmaceutical Co., Ltd. (Xi'an, China) (Approval
No. 091201).
Tau-5 antibody (for total tau) was purchased from Bio-
source Company (Beijing, China), and was diluted at a
ratio of 1∶1000 during western blotting.
P-tau-Thr231 antibody was obtained from Novous Bio
Company (Littleton, CO, USA), and was diluted at a
ratio of 1∶400 during immunohistochemistry staining
and 1∶1000 during western blotting.
P-tau-Ser422 antibody (Immunohistochemistry) was
purchased from Abcam Company (Burlingame, CA,
USA), and was diluted at a ratio of 1∶200 during im-
munohistochemistry staining. P-tau-Ser422 antibody
(western blotting) was obtained from Biosource Com-
pany (Beijing, China), and was diluted at a ratio of 1:
1000 during western blotting. The secondary antibody,
HRP-labeled Goat Anti-Rabbit IgG (H + L) was pur-
chased from Beyotime Company (Shanghai, China).
SAD model establishment
According to Sharma,8 rats were anesthetized with
10% chloral hydrate and then placed on the stereotaxis
instrument. Following routine skin disinfection, a me-
dian sagittal incision was made in the rats' skull and
dura mater was removed to expose the endocranium.
Streptozotocin was dissolved with artificial cerebrospi-
nal fluid (25 mg/mL) and 18 μL was administered [in-
tracerebroventricularly (i.c.v.)] with a microinjector to
rats in all groups (except the sham-operation group).
Sham-operated rats received (i.c.v.) artificial cerebrospi-
nal fluid (at the same volume). Coordinations were
made according to The Rat Brain in Stereotaxic Coor-
dinates.9 The same administration was given again 2
days later.
Treatments
XXD and donepezil were administered 21 days after
the second injection of streptozotocin or artificial cere-
brospinal fluid. All doses of XXD were prepared by dis-
solving XXD granules with double distilled water (at
60℃ ). An extract of 29 g was equivalent to 169 g of
crude medicinal. From this extract, 7.61, 15.21, and
30.42 g/kg-1·d-1 was administered for the low-dose,
moderate-dose, and high-dose groups, respectively.
Donepezil was administered at 0.92 mg/kg and given
at 7.5 mg/kg-1·d-1 by gavage. The model group and
sham-operation groups were given the same amount of
double distilled water by gavage. All treatments lasted
for 2 months.
Morris Water Maze task10,11,7
The place navigation experiment is used to measure
the learning and memory abilities of animals in the wa-
ter maze. The animals swim freely for 2 min before the
experiment. During the experiment, the animals are
trained twice daily each for 120 s for 5 d. Select a quad-
rant adjacent to the quadrant in which the platform lo-
cated, and put the rats facing the wall into the water
from the selected quadrant and record the time for
them to find the platform and climb up. This time
span is called escape latency. Swimming distance is also
recorded. If the rat does not find the platform in 120 s,
it will be brought out of the water by the experimenter
to the platform and stays there for 20 s. For such rats
the escape latency is recorded as 120 s. Spatial probe
test is used to measure the memory ability of the accu-
rate location of the platform, namely, memory reten-
tion. Remove the platform on the 6th day, choose any
place to put the rats into the water to swim for 120 s
and record the swimming time of rats in the target
quadrant (the quadrant in which the platform is locat-
ed) and other quadrants, respectively
Brain tissue sample treatment
Six rats from each group were randomly selected for
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perfusion fixation. The rats were anesthetized with
10% chloral hydrate (4.0 mL/kg) via intraperitoneal in-
jection and were then placed in a supine posture with
four extended limbs fixed to the board. The chest was
opened, exposing the heart and liver. A catheter was
then rapidly plugged into the ascending aorta through
the left ventricle for fixation (At the same time the right
auricle was cut open). Physiological saline (100 mL)
was infused rapidly until the liver turned pale. When
clear liquid exited the right ventricle, 4% paraformalde-
hyde was infused continuously for 30 min from fast to
slow speed. Rats were then decapitated, and their brains
removed and placed in fixative liquid. After 24 h, coro-
nal sections (5 μm) were made from the hippocampal
CA1 region, and placed in 0.01 M phosphate-buffered
saline with Tween (PBST, By the 8.5 g sodium chlo-
ride, disodium hydrogen phosphate 3.15 g, sodium di-
hydrogen phosphate 0.2 g add distilled water volume
to 1 L, and then add 1 mL tween 20 dubbed buffer) so-
lution for immunohistochemistry. For western immu-
noblotting, fresh hippocampus was removed and
placed in liquid nitrogen (for snap freezing) and then
stored at﹣70℃.
Immunohistochemistry
Paraffin sections were deparaffinized with xylene. After
endogenous peroxidase activity was blocked with 3%
H2O2, sections were washed with distilled water, then
placed in citrate buffer (pH 6.0) for heat-mediated an-
tigen retrieval followed by washes with PBS (pH 7.4).
Sections were sealed by the incubation (37℃ for
20 min) with 5% bull serum albumin. Sections were
incubated (4℃ , overnight) with primary antibody (di-
lution as previously described) followed by the second-
ary antibody (1 h at 37℃ ). Dolichos biflorus aggluti-
nin (Beijing, China) was added to the sections for
5-30 min at room temperature followed by incubation
with streptavidin-biotin (Beijing, China) and horserad-
ish peroxidase for 1 h at 37℃ . After hematoxy-
lin-and-eosin staining and dehydration in a graded se-
ries of alcohol, sections were cleared in xylene and
sealed with neutral balsam.
Images of brain slices from the same position of each
rat were collected and analyzed via digital medical im-
age analysis system Motic Med 6.0 (Xiamen, China).
Positive cell counts, total area of positive cells as well as
integral optical density from each group of images were
recorded.
Western immunoblot analysis
Hippocampal proteins were extracted using Folin-phe-
nol reagent (Beijing, China). Sodium dodecyl sulfate
polyacrylamide gel electrophoresis. Immune response
(add related second antibody diluted at a ratio of 1:
1000 respectively). Chemiluminescence reaction (sip
up PBST on the membrane and lay the membrane on
a clean plate with membrane protein on the top).
Bands were detected by the Obscura camera with the
Syngene GBOX iChemi multi-functional chemilumi-
nescence gel imaging system. The optical density of
each band was analyzed by the digital medical image
analysis system.
Statistical analysis
All data are expressed as the mean±standard deviation
(SD) followed by a one-way analysis of variance anal-
ysis. The data were processed by the SPSS 17.0 statis-
tical software package (IBM, Armonk, NY, USA).
Significance was reached at values of P<0.05 or P<
0.01.
RESULTS
Behaviors test
During the place navigation test, the mean escape la-
tency and total swimming distance on the 3rd trial day
of the 5-day navigation task was significantly (P<0.05)
different in the donepezil group, and in all three doses
of XXD, compared with the model group. On the 5th
trial day, the mean escape latency and total swimming
distance in all treatment groups was significantly (P<
0.01) different compared with the model group (Ta-
bles 1, 2). During the spatial probe trial (performed on
the 6th day), the rats in the model group stayed longer
in the outer region of the target quadrant but had few-
er activities around the target quadrant compared with
the sham-operated group (P<0.01). Compared with
the model group, the swimming time in the target
quadrant of rats in all treatment group became signifi-
cantly longer (P<0.01 or P<0.05).
Group
S
M
D
YL
YM
YH
n
11
12
12
11
11
11
Day 1
77±257
95±7
79±24
69±42
57±20a
66±21a
Day 2
31±11
89±26b
67±26
61±29a
41±19c
27±10cd
Day 3
20±10
51±32b
28±17a
26±20a
27±21a
20±12c
Day 4
13±3
47±30b
28±26a
24±11a
31±28a
17±12c
Day 5
11±7
40±34b
16±14c
17±13c
20±23c
11±8c
Table 1 Escape latency for the navigation task for all groups (s, xˉ ±s)
Notes: S: sham-operation group; M: model group; D: donepezil group; YL: XXD low-dose group; YM: XXD moderate-dose group; YH:
XXD high-dose group. XXD: Xixin decoction. aP<0.05, cP<0.01 vsM group; bP<0.01 vs S group; dP<0.05 vs D group.
789
JTCM |www. journaltcm. com December 15, 2013 |Volume 33 | Issue 6 |
DiwuYC et al. / Experimental Study
Western blot test result
Western immunoblot analyses revealed that the expres-
sion of P-Thr231 and P- Ser422 was significantly (P<
0.01) higher in the model group compared with
sham-operated animals. However, expression of these
two phosphorylated proteins were significantly (P<
0.05) lower in all three doses of XXD treatment com-
pared with the model group. No significant difference
was found between all three doses of XXD and be-
tween the donepezil group and the model group. No
significant difference in the expression of total tau was
found between all groups (Figure 1-3).
Immunohistochemical detection
Cell counts, total area measurements, and integral opti-
cal densities of P-Thr231- and P-Ser422-positive cells
(Tables 3, 4) revealed that all of these parameters were
significantly (P<0.01) increased in the model group
compared with sham-operated animals. However, all
three doses of XXD treatment significantly (P<0.05) re-
duced all three parameters compared with the model
group. There was no marked difference between all
Figure 3 P-Ser422 expression in the rat hippocampus
among different groups
A: representative immunoblot of P-Ser422; B: relative abun-
dance of P-Ser422 normalized to β-actin. S: sham-operation
group; M: model group; D: donepezil group; YL: XXD
low-dose group; YM: XXD moderate-dose group; YH: XXD
high-dose group. XXD: Xixin decoction. P-Ser422: Phosphor-
ylation at the site of Ser422 on tau proteins. aP<0.01 vs S
group; bP<0.01 vsM group; cP<0.01 vs D group.
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Figure 1 Tau-5 expression in the rat hippocampus among
different groups
A: representative immunoblot of Tau-5; B: relative abun-
dance of Tau-5 normalized to β-actin. S: sham-operation
group; M: model group; D: donepezil group; YL: XXD
low-dose group; YM: XXD moderate-dose group; YH: XXD
high-dose group. XXD: Xixin decoction.
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Figure 2 P-Thr231 expression in the rat hippocampus
among different groups
A: representative immunoblot of P-Thr231; B: relative abun-
dance of P-Thr231 normalized to β-actin. S: sham-operation
group; M: model group; D: donepezil group; YL: XXD
low-dose group; YM: XXD moderate-dose group; YH: XXD
high-dose group. XXD: Xixin decoction. P-Thr231: Phosphor-
ylation at the site of Thr231 on tau proteins. aP<0.01 vs S
group; bP<0.01 vsM group; cP<0.01 vs D group.
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Group
S
M
D
YL
YM
YH
n
11
12
12
11
11
11
Day 1
969±368
1211±304
1063±408
822±545 a
743±314a
969±400
Day 2
677±409
1094±498b
756±348a
666±494a
530±330c
422±205cd
Day 3
334±175
764±376e
452±272a
328±174c
361±206c
342±172c
Day 4
231±23
749±376e
408±245a
317±146c
462±388a
252±123c
Day 5
179±106
602±409e
247±225c
261±216c
308±311c
157±105c
Notes: S: sham-operation group; M: model group; D: donepezil group; YL: XXD low-dose group; YM: XXD moderate-dose group; YH:
XXD high-dose group. XXD: Xixin decoction. bP<0.05, eP<0.01 vs S group; aP<0.05, cP<0.01 vsM group; dP<0.05 vs D group.
Table 2 Swimming distance for the navigation task for all groups (cm, xˉ ±s)
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Group
S
M
D
YL
YM
YH
n
6
6
6
6
6
6
Positive cells count
13.0±0.9
61.7±1.6a
55.0±0.9
43.7±1.9bd
18.1±1.0ce
14.4±0.7ce
Total positive area (µm2)
5677.8±164.3
19833.6±734.1a
18998.2±693.9
14858.2±412.3bd
7525.5±200.7ce
6730.6±170.9ce
Integral optical density (OD)
39.6±0.8
148.7±2.4a
133.6±4.1
122.6±1.9b
54.5±1.8ce
57.9±3.3ce
Notes: S: sham-operation group; M: model group; D: donepezil group; YL: XXD low-dose group; YM: XXD moderate-dose group; YH:
XXD high-dose group. XXD: Xixin decoction. aP<0.01 vs S group; bP<0.05, cP<0.01 vsM group; dP<0.05, eP<0.01 vs D group.
Table 3 P-Thr 231 expression in CA1 region of hippocampus of rat by immunohistochemistry ( xˉ ±s)
Group
S
M
D
YL
YM
YH
n
6
6
6
6
6
6
Positive cells count
13.6±0.9
64.9±2.4a
61.8±0.4
43.6±0.9bc
18.7±0.5bc
16.6±0.4bc
Total positive area (μm2)
4259.9±206.4
22263.1±953.2a
20376.5±510.6
15851.0±188.8bc
7570.6±80.7bc
5492.6±94.0bc
Integral optical density (OD)
41.9±1.0
163.2±1.2a
153.4±0.5
121.3±1.1bc
49.2±0.3bc
48.2±0.9bc
Notes: S: sham-operation group; M: model group; D: donepezil group; YL: XXD low-dose group; YM: XXD moderate-dose group; YH:
XXD high-dose group. XXD: Xixin decoction. aP<0.01 vs S group; bP<0.01 vsM group;, cP<0.01 vs D group.
Table 4 P-Ser422 expression in CA1 region of hippocampus of rat by immunohistochemistry ( xˉ ±s)
A B C
D E F
Figure 4 P-Thr 231 expression in CA1 region of hippocampus of rat by immunohistochemistry (Immunohistochemical staining, ×
200)
A: sham group: negligible presence of positive cells; B: model group: higher presence (deeply stained cytoplasm) of positive cells;
C: donepezil group: prominent presence of positive cells; D: XXD low-dose group: prominent presence of positive cells, E: XXD
moderate-dose group: lower presence of positive cells; F: XXD high-dose group: lower presence of positive cells.
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three XXD groups, and between the donepezil and
model group (Figures 4A, 4F, 5A, 5F). Presence of posi-
tive cells in the sham-operation group was negligible;
however, those of the model group were detected by
their deeply stained cytoplasm. Presence of positive
cells in the donepezil group and XXD low-dose group
was observed to be high; however, those for the XXD
moderate-dose group and XXD high-dose group were
lower.
DISCUSSION
In recent years, a milestone discovery was made on the
molecular mechanism of AD, revealing hyperphosphor-
ylation of microtubule-associated tau proteins as the
major protein component of paired helical filaments
(PHF), which is contained in neurofibrillary tangle
(NFTs), and is thus a histopathological hallmark of
AD. Accumulation of PHF of tau proteins is modified
via ubiquitination, ammonification, non-enzymatic gly-
cosylation, nitrification and partial hydrolization, there-
by forming late PHF/NFT.12 A recent study has shown
that hyperphosphorylation of tau proteins facilitates
AD neurodegeneration by cytotoxicity,3 and that forma-
tion of intracellular insoluble PHF/NFT may be a cel-
lular defense reaction to reduce the toxicity.13 Further-
more, phosphorylation of Thr231/Ser235, Ser422,
Ser199/Ser202/Thr205, Thr212, and Ser262/Ser356
may convert tau proteins into toxic molecules,14 thus
inhibiting the physiological functions of tubulin pro-
tein.4 Further phosphorylation of Thr231, Ser422, and
Ser396 may deposit tau proteins as NFT.3
XXD treatment in the present study is an optimized ex-
tract with modified ingredients and doses from the
well-known formula prescribed by Shiduo Chen in the
Qing Dynasty for the treatment of dementia. Accord-
ing to the treatment principle of replenishing Qi and
reinforcing Yang, and relieving stagnation and resolv-
ing phlegm, the formula is intended for both resolving
and nourishing. This is achieved by considering both
the interior and exterior. Thus, Qi and Yang are in-
creased, Yin pathogenic factors are removed, stagnation
and resolving phlegm is relieved, and Yin and Yang are
balanced. Pilot studies have shown that XXD improves
spatial learning and memory in SAD rats by intracere-
broventricular injection of Streptozotocin, with the
protection of mitochondria and axonal microtubule
structure in hippocampal neurons.7
The current study showed that XXD reduced the ex-
pression of P-Thr 231 and P- Ser422 in SAD rats, sug-
gesting that this medicine inhibits hyperphosphoryla-
tion of tau proteins at P-Thr231 and P-Ser422 sites.
Hyperphosphorylation at these sites facilitates tau ag-
gregation in the brain, thus dramatically reducing com-
bined tau and microtubule, which blocks the assembly
A B C
D E F
Figure 5 P-Ser422 expression in CA1 region of hippocampus of rat by immunohistochemistry (Immunohistochemical staining, ×
200)
A: sham group: negligible presence of positive cells; B: model group: higher presence (deeply stained cytoplasm) of positive cells;
C: donepezil group: prominent presence of positive cells; D: XXD low-dose group: prominent presence of positive cells; E: XXD
moderate-dose group: lower presence of positive cells; F: XXD high-dose group: lower presence of positive cells.
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process of microtubule. Consequently, transportation,
storage and release of related neurotransmitters are dis-
turbed, directly leading to learning and memory im-
pairment.15 XXD may effectively correct this pathologi-
cal process by inhibiting the hyperphosphorylation at
Thr231 and Ser422 sites of tau proteins. Further stud-
ies should focus on the mechanisms of hyperphosphor-
ylation of tau proteins and the formation of pathologi-
cal fibrous structures.
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